Title: Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
Journal: Bioorganic & medicinal chemistry letters 20121115
Title: [Progress in the ligands and their complex structures of farnesoid X receptor].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20120601
Title: Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP).
Journal: American journal of physiology. Gastrointestinal and liver physiology 20090701
Title: The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20070901
Title: 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
Journal: Bioorganic & medicinal chemistry letters 20070415
Title: The farnesoid X receptor: a novel drug target?
Journal: Expert opinion on investigational drugs 20040901
Title: A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
Journal: Molecular cell 20030401
Title: N-hydroxyamobarbital: the second major metabolite of amobarbital in man.
Journal: Drug metabolism and disposition: the biological fate of chemicals 19750101
Title: Lam IP, et al. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G90-7.
Title: Michael Downes, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003 Apr;11(4):1079-92.
Title: Fang S, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb;21(2):159-65.